On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

RAPSN

receptor associated protein of the synapse

The RAPSN gene provides instructions for producing rapsyn, a protein crucial for anchoring acetylcholine receptors at the neuromuscular junction, which is vital for muscle contraction. The RAPSN gene is essential for proper communication between nerves and muscles.

Chromosome 11p11.2 Autosomal recessive HGNC:9863 Tier C
RAPSN 11p11.2 p arm q arm 11

RAPSN is located on the short (p) arm of chromosome 11, at band 11p11.2. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 11 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The RAPSN gene, or receptor associated protein of the synapse, is fundamental to the function of the neuromuscular junction. This specialised area facilitates communication between nerve cells and muscle cells, enabling voluntary muscle contractions. The protein produced from the RAPSN gene plays a critical role in ensuring these signals are effectively relayed and received by muscles, making it central to normal muscle movement.

What the gene does

The RAPSN gene directs the synthesis of the rapsyn protein. Rapsyn is responsible for binding to the subunits of the acetylcholine receptor (AChR), a crucial protein located in the muscle cell membrane. By binding to these subunits, rapsyn helps to keep them together and firmly anchors the complete AChR protein within the muscle cell membrane. The precise positioning and stability of the AChR are vital for the proper function of the neuromuscular junction, as it is through these receptors that nerve signals are received by muscle cells, triggering movement. Disruptions to this anchoring mechanism can impair signal transmission, leading to muscle weakness.

Video: Genetics 101

Chromosome location

The RAPSN gene is situated on the short arm of chromosome 11 at position 11.2, denoted as 11p11.2. This specific genomic location places it within a region of the genome that is actively studied for its role in various biological processes.

Protein structure

The RAPSN protein is composed of 412 amino acids and features a complex domain architecture. It contains seven tetratricopeptide repeat (TPR) domains, specifically TPR 1 (amino acids 6-39), TPR 2 (amino acids 83-116), TPR 3 (amino acids 123-156), TPR 4 (amino acids 163-196), TPR 5 (amino acids 206-239), TPR 6 (amino acids 246-279), and TPR 7 (amino acids 286-319). Additionally, the protein includes a RING-type (Zinc finger) domain spanning amino acids 363-403, which typically mediates protein-protein interactions.

Domain map · 412 amino acids
TPR 1 (6-39)TPR 2 (83-116)TPR 3 (123-156)TPR 4 (163-196)TPR 5 (206-239)TPR 6 (246-279)TPR 7 (286-319)RING-type (363-403)TPR 16-39TPR 283-116RING363-4031~206412
Repeat - repeating structural motif
Zinc finger - zinc-binding structural motif
🧬 Explore 3D structure on AlphaFold
UniProt:Q13702Length:412 aaStructure:AlphaFold

Key variants

Variants within the RAPSN gene can alter the structure or function of the rapsyn protein. These genetic changes may disrupt the protein's ability to properly assemble and anchor acetylcholine receptors at the neuromuscular junction. The consequences of such variants can range from mild to severe, depending on their specific impact on protein function and receptor stability.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for RAPSN.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1166+1G>T
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Fetal akinesia deformation sequence 1
c.192+2T>G
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Congenital myasthenic syndrome 11
c.1A>G
single nucleotide variant
p.Met1Val Pathogenic/Likely pathogenic ★★☆☆ Fetal akinesia deformation sequence 1
c.210del
Deletion
p.Ile70fs Pathogenic/Likely pathogenic ★★☆☆ Congenital myasthenic syndrome
c.213dup
Duplication
p.Thr72fs Pathogenic/Likely pathogenic ★★☆☆ Congenital myasthenic syndrome
c.288del
Deletion
p.Cys97fs Pathogenic/Likely pathogenic ★★☆☆ Congenital myasthenic syndrome 11
c.358del
Deletion
p.Gln120fs Pathogenic ★★☆☆ RAPSN-related disorder
c.3G>T
single nucleotide variant
p.Met1Ile Pathogenic ★★☆☆ Fetal akinesia deformation sequence 1
c.531+1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Congenital myasthenic syndrome
c.733C>T
single nucleotide variant
p.Gln245Ter Pathogenic/Likely pathogenic ★★☆☆ Fetal akinesia deformation sequence 2

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in the RAPSN gene are associated with various forms of congenital myasthenic syndromes. Specifically, changes in RAPSN can lead to Congenital myasthenic syndrome (RAPSN), an inherited condition characterised by muscle weakness and fatigue. These syndromes arise from impaired communication between nerves and muscles, often due to issues with the acetylcholine receptor at the neuromuscular junction.

Inheritance pattern

Conditions caused by pathogenic RAPSN variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous RAPSN carrier status across ancestry groups?

UK clinical status

The RAPSN gene is recognised within the NHS Genomic Medicine Service due to its clinical significance. It is listed on several PanelApp panels, including Arthrogryposis (green, R83), Congenital myaesthenic syndrome (green, R80), DDG2P (green), and Foetal anomalies (green, R21), indicating that variants in this gene are considered to have a strong association with these conditions in a diagnostic setting.

Frequently asked questions

What is the primary function of the RAPSN gene?

The RAPSN gene provides instructions for making the rapsyn protein, which helps to assemble and anchor acetylcholine receptors at the neuromuscular junction. This function is essential for transmitting nerve signals to muscles, enabling muscle contraction.

What health conditions are associated with variants in the RAPSN gene?

Variants in the RAPSN gene are primarily associated with congenital myasthenic syndromes, including Congenital myasthenic syndrome (RAPSN). These conditions are characterised by muscle weakness and fatigue due to impaired neuromuscular signalling.

How is the RAPSN gene inherited?

The RAPSN gene is inherited in an autosomal recessive (AR) pattern. This means an individual must inherit two copies of a pathogenic variant, one from each parent, to develop a condition associated with this gene.

References

  1. Engel AG. Congenital myasthenic syndromes in 2012. Current neurology and neuroscience reports. 2012. PMID: 21997714
  2. Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscular disorders : NMD. 2012. PMID: 22104196
  3. Barišić N, Chaouch A, Müller JS. Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2011. PMID: 21498094
  4. Milone M, Shen XM, Selcen D. Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients. Neurology. 2009. PMID: 19620612
  5. Beeson D, Webster R, Cossins J. Congenital myasthenic syndromes and the formation of the neuromuscular junction. Annals of the New York Academy of Sciences. 2008. PMID: 18567858
  6. Kinali M, Beeson D, Pitt MC. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of neuroimmunology. 2008. PMID: 18707767
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 18 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .